Mumtaz Aqsa, Sheikh Abdul Ahad Ehsan, Khan Amin Moazzam, Khalid Subaina Naeem, Khan Jehanzaeb, Nasrullah Adeel, Sagheer Shazib, Sheikh Abu Baker
Department of Internal Medicine, Montefiore St. Luke's Cornwall Hospital, Newburgh, NY 12550, USA.
Department of Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, PA 18505, USA.
Life (Basel). 2022 Jul 16;12(7):1066. doi: 10.3390/life12071066.
As the COVID-19 pandemic progresses, changing definitions and therapeutics regarding the post-acute sequela of COVID-19, particularly long COVID, have become a subject of great interest and study. The study aims to describe the pathophysiology and discuss different therapeutic agents currently available for long COVID. Another objective is to assess comparative efficacy between different types of vaccines on symptoms of long COVID. A preliminary search was conducted using Ovid Medline, Embase, medRxiv, and NIH COVID-19 portfolios. A total of 16 studies were included in our review. Despite some of the data showing variable results, most of the vaccinated patients reported improvement in long COVID symptoms with no significant difference between various types of vaccines. Further trials are needed to better identify the comparative efficacy of vaccines for long COVID and ascertain other therapeutic modalities.
随着新冠疫情的发展，关于新冠后遗症，尤其是长期新冠的定义和治疗方法不断变化，已成为备受关注和研究的课题。该研究旨在描述其病理生理学，并讨论目前可用于治疗长期新冠的不同治疗药物。另一个目标是评估不同类型疫苗对长期新冠症状的比较疗效。使用Ovid Medline、Embase、medRxiv和美国国立卫生研究院新冠病毒研究项目进行了初步检索。我们的综述共纳入了16项研究。尽管一些数据显示结果存在差异，但大多数接种疫苗的患者报告称长期新冠症状有所改善，不同类型疫苗之间无显著差异。需要进一步试验以更好地确定疫苗对长期新冠的比较疗效，并确定其他治疗方式。
